Sign in
Taking people in United StatesNo phase

Using near-infrared light to study blood flow in peripheral artery disease

Studies blood flow and oxygen use in the legs of people with peripheral artery disease.

Key facts

Who runs it
The University of Texas at Arlington
Where
Arlington, United StatesSee the 2 sites
Trial code
Registry title
Using Near-Infrared Light to Better Understand Peripheral Artery Disease
Status
Recruiting
People taking part
120 people, planned
Started
1 Nov 2025
Expected to end
31 Dec 2028
Type of study
Observational, 2 groups
Record updated
2 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with peripheral artery disease (narrowed leg arteries) confirmed by a doctor. It is also looking for healthy people without this disease as a comparison group.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Patients: peripheral artery disease confirmed by a doctor, with an Ankle-Brachial Index between 0.4 and 0.9. Healthy volunteers: no symptoms and no history of the disease.
Earlier treatment
For the second part, patients must have completed the first part of the study.
Biomarker or test result
Ankle-Brachial Index (a blood pressure test comparing ankle and arm) not above 0.9 and not below 0.4.

Main reasons for not taking part

  • Unstable chest pain (angina) or heart attack in the past 12 months.
  • Reasons you cannot have an MRI scan, such as a pacemaker, cochlear implant, permanent jewelry, pregnancy, or continuous oxygen therapy.
  • Not able to walk 10 feet, or physical limits that prevent the tests.
  • Patients: disease only in the aorta or iliac (pelvic) arteries.
  • Healthy volunteers: heart or lung disease (mild asthma allowed), current tobacco use, or blood pressure above 150/90 mmHg.

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Cases, Aim 1; 18 or older; willing to participate under the conditions described in the informed consent form (ICF); eligible to sign the ICF; established diagnosis of PAD confirmed by a physician; able to comply with the study requirements
  • Cases, Aim 2; completed Aim 1
  • Controls 1) asymptomatic, with no history or diagnosis of peripheral artery disease

Who cannot take part

  • Cases, Aim 1; Ankle-Brachial Index >0.9 or <0.4; isolated disease in aorta/iliac vessels; unstable angina or myocardial infarction in past 12 months; orthopedic or other physical limitations which would prevent data collection; contraindications to MRI, including presence of a Pacemaker, presence of bone growth/ bone fusion stimulators, presence of tissue expander, presence of cochlear implants, unable to ambulate for 10 feet, receiving continuous Oxygen therapy, pregnancy, permanent Jewelry (screened using MRI safety screening form and verbal screening by MRI operator
  • Cases, Aim 2; unstable angina or myocardial infarction in past 12 months; orthopedic or other physical limitations which would prevent data collection; contraindications to MRI, including presence of a pacemaker, presence of bone growth/ bone fusion stimulators, presence of tissue expander, presence of cochlear implants, unable to ambulate for 10 feet, receiving continuous Oxygen therapy, pregnancy, permanent Jewelry (screened using MRI safety screening form and verbal screening by MRI operator)
  • Controls 1) history of peripheral artery disease 2) overt cardiovascular disease (e.g. heart failure) 3) known pulmonary disease (excluding mild asthma) 4) current tobacco use 5) orthopedic or other physical limitations which would prevent data collection, 6) BP >150/90 mmHg at screening 7) contraindications to MRI, including presence of a pacemaker, presence of bone growth/ bone fusion stimulators, presence of tissue expander, presence of cochlear implants, unable to ambulate for 10 feet, receiving continuous Oxygen therapy, pregnancy, permanent Jewelry (screened using MRI safety screening form and verbal screening by MRI operator)

Where in United States

  • University of Texas ArlingtonArlington, United StatesContact: Rajvi Shah, MPHNot yet recruiting
  • University of Texas at ArlingtonArlington, United StatesContact: Rajvi ShahTaking people

About the trial

What the trial wants to find out

The goal of this study is to better understand how blood flows and how oxygen is utilized in the lower limbs of people who suffer from peripheral artery disease. This study will also assess how these factors affect treatment outcomes.

Read full original descriptionShow less

Specific aims include:

Aim 1: Utilize BB-NIR-DCS to differentiate PAD patients experiencing primary oxygen delivery limitations from those suffering from mitochondrial dysfunction.

Aim 2: Test the efficacy of BB-NIR-DCS at predicting individual responses to vascular intervention.

The 2 groups in the trial

  • Healthy Controls

    Individuals without PAD

  • Cases with PAD

    Individuals with PAD

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Near-Infrared Diffuse Correlation Spectroscopy to Better Define the Pathophysiology of Peripheral Artery Disease
Plain-language title
Using near-infrared light to study blood flow in peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
2 January 2026